Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Patient Voice
Open Access

A Patient’s Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis

Cher Thomas
CJASN June 2020, 15 (6) 743-744; DOI: https://doi.org/10.2215/CJN.05150420
Cher Thomas
Galveston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • benzodiazepines
  • opioids
  • hemodialysis
  • analgesics
  • opioid
  • renal dialysis
  • drug prescriptions

I am commenting on the article appearing in CJASN entitled “Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis,” by Muzaale et al. (1). I am a registered dental hygienist. I have lived with chronic pain for decades, and I greatly appreciate the opportunity to offer my comments on this article.

My opinions are on the basis of my experience as a kidney patient and as a chronic pain patient (both for 22 years), and on the basis of my education and professional experience as an allied health care provider for roughly 40 years. The cause of my kidney disease and the majority of my chronic pain is an autoimmune disorder. However, I also have repetitive occupational injuries, due to my professional obligations of treating patients.

I am encouraged to see the crisis of palliative care being addressed in the kidney population. Obviously, opioids aren’t the only crisis that should be addressed. Although I am thankful to see other sources of respiratory crisis investigated, I am left wondering, “Why would a benzodiazepine be coprescribed with an opioid, regardless of whether it is short- or long-acting?” A mortality risk of 1.9-fold for short-acting benzodiazepine with an opioid is self-explanatory. However, I was confused by the authors’ explanation of the mortality risk of long-acting coprescribed benzodiazepine as “no differential risk”; yet, “these results should be interpreted with caution as there is always the potential for channeling bias, unmeasured/unmeasurable confounders or other forms of bias that would lead to a non-causal association.”

Although the statistics from the study were from 2013 to 2014, I was surprised to learn that “benzodiazepine mortality had already been identified as a growing concern for white women.” I am a white female with chronic pain for the last 22 years. I interact with other kidney patients regularly and chronic pain/depression is something I hear about from all patients, not only white females. I firmly believe that patients, other than white females, live with the same struggles as I do.

I am thankful to have a nephrology team that listens to my concerns and struggles. With chronic pain, if you don’t start out with depression, you will eventually find yourself depressed. I feel like a criminal when I am faced with requesting a prescription for my chronic pain. Minorities and men likely feel the same physical challenges as I do but are afraid to discuss them with their doctors. They may even experience bias due to preconceived stigmas of addiction or that they might sell their medication for profit. It is important that our health care professionals remember to engage with patients, rather than avoiding discussions about our pain management.

I live south of Houston, Texas. I waited 10 months to see a neurologist at my local hospital, which has a chronic shortage of neurologists. I’ve been to pain management, which recommended injections into my cervical spine every 3 months with sedation. And, when that failed, the pain management center referred me back to my nephrologist, because they didn’t want to harm my transplant. They had essentially run out of treatments. I have full medical coverage, so going to multiple specialists is fortunately a small burden to me. Other patients are not as lucky. Limited access to care is yet another hurdle for patients and a reason why they might not report chronic pain.

I am thankful for the opportunity to share my thoughts about this article and to the nephrology teams that work tirelessly to keep us (your patients) safe. I am grateful for your expertise and dedication, even in the time of chaos and a global pandemic. You are all truly heroes.

I am especially thankful to have a nephrology team that cares about my wellbeing and continually assists me in the management of my pain and my kidney health, for they are both a part of me. In the future, when COVID-19 has subsided, I hope to see more advances, research opportunities, and treatment options in palliative care for all people who have kidney disease.

Disclosures

Ms. Thomas has nothing to disclose.

Funding

None.

Acknowledgments

Ms. Thomas is a renal transplant recipient and a registered dental hygienist. In addition to being a patient advocate with the Kidney Support Network, Ms. Thomas has authored several articles in dental and dental hygiene publications regarding the dental management of patients with CKD, ESKD, and kidney transplantation. She welcomes comments to Catblue30{at}aol.com.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis,” on pages 794–804.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Muzaale AD,
    2. Daubresse M,
    3. Bae S,
    4. Chu NM,
    5. Lentine KL,
    6. Segev DL,
    7. McAdams-DeMarco M
    : Benzodiazepines, codispensed opioids, and mortality among patients initiating long-term in-center hemodialysis. Clin J Am Soc 15: 794–804, 2020
    OpenUrl
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (6)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 6
June 08, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
A Patient’s Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Patient’s Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
Cher Thomas
CJASN Jun 2020, 15 (6) 743-744; DOI: 10.2215/CJN.05150420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
A Patient’s Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
Cher Thomas
CJASN Jun 2020, 15 (6) 743-744; DOI: 10.2215/CJN.05150420
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Patients with Kidney Disease: Ready to Use Smartphones for Health Care Delivery?
  • Fatigue While Undergoing Long-Term Hemodialysis
  • Improving the Evaluation Process for Potential Living Kidney Donor Candidates
Show more Patient Voice

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
  • PubMed
  • Google Scholar

Keywords

  • Benzodiazepines
  • opioids
  • hemodialysis
  • Analgesics
  • Opioid
  • renal dialysis
  • drug prescriptions

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire